Stop Overdose Deaths Arizona

SODAz, or Stop Overdose Deaths Arizona, is a partnership of AzPA and the Maricopa County Department of Public Health. Our goal is to increase accessibility of nasal naloxone, reduce deaths by educating the public, and diminish the stigma's related to substance use disorder.

AzPA Legacy Intern Application

An AzPA Legacy Intern is a student member of the AzPA Mentor Connection Program who hopes to stay in Arizona after graduating from an Arizona college of pharmacy in 2026.

Due: Noon on Monday, December 2!

2025 Spring Clinical

REGISTRATION IS NOW OPEN!

Join us for our Spring Clinical Conference, happening at Creighton University on February 15, 2025!

2025 Annual Convention

JUNE 12-15, 2025 | Tucson

Save the date for our Annual Convention! We'll be at the Westin La Paloma in Tucson! Can't wait to see you there...

Refresh Your AzPA Profile!

When was the last time you checked your AzPA profile? Things change all the time - cell numbers, emails, etc. Take a minute and log in so we can get in touch with you!

Login Here

Education

Learn with us

Advocacy

Discover your voice

Connection

Get involved! Serve on a team

RSS AzPA Pharmacy Flash

  • Can Suboxone (buprenorphine-naloxone) help treat pain?
    Suboxone, a prescription medication for opioid use disorder, contains buprenorphine and naloxone as active ingredients. It provides similar analgesic effects to opioids without severe side effects. Off-label use of buprenorphine-naloxone for pain management is also available.
  • American Associated Pharmacies struck by ransomware attack
    American Associated Pharmacies has been targeted by a ransomware attack, stealing over 1.4 terabytes of data and demanding $1.3 million to decrypt it. The attack follows previous ransomware attacks on Memorial Hospital and Manor and Weiser Memorial Hospital.
  • Pharmacists' key role in the management of Humira biosimilars
    The introduction of adalimumab biosimilars to the U.S. market in 2023 has brought significant changes for providers, patients and pharmacies. Humira, a bestselling drug for treating inflammatory conditions, has been approved for nine biosimilars, including adalimumab-ryvk.

Upcoming Events

Upcoming Events

ENDORSED PARTNER OF AzPA

ENDORSED PARTNER OF AzPA

ENDORSED PARTNER OF AzPA

ENDORSED PARTNER OF AzPA

ENDORSED PARTNER OF AzPA

ENDORSED PARTNER OF AzPA